HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates
Executive Summary
The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.
You may also be interested in...
J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV
Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.
NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount
UK HTA gives provisional backing to Merck’s once-daily fixed-dose hepatitis C combo Zepatier after the US drug maker offers an undisclosed price cut.
Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing
Gilead's sofosbuvir/velpatasvir combination Epclusa and Merck's grazoprevir and elbasvir combo Zepatier are on course for approval in Europe for treating hepatitis C, but analysts say Gilead's two-drug therapy has the better commercial prospects of the two.